1 |
(cdp6038 |
- |
- |
- |
- |
046 [1] 46 💬 |
2 |
2-cda |
Cladribine |
[1] D01370 D01370 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
013 [1] 13 💬 |
3 |
2-cda, 2-chloro-2'-deoxy-beta-d-adenosine |
Adenosine |
[2] D00045 D00045, D01370 D01370 💬 |
ADORA1 [5] ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism [17] Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 [1] 13 💬 |
4 |
2-cda, 2-chloro-2'-deoxy-ß-d-adenosine |
Adenosine |
[2] D00045 D00045, D01370 D01370 💬 |
ADORA1 [5] ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism [17] Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 [1] 13 💬 |
5 |
2-cda, 2-chloro-2?-deoxy-beta-d-adenosine |
Adenosine |
[2] D00045 D00045, D01370 D01370 💬 |
ADORA1 [5] ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism [17] Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 [1] 13 💬 |
6 |
2-cda, 2-chloro-2?-deoxy-ß-d-adenosine |
Adenosine |
[2] D00045 D00045, D01370 D01370 💬 |
ADORA1 [5] ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism [17] Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 [1] 13 💬 |
7 |
2-cda, 2-chloro-2’-deoxy-beta-d-adenosine |
Adenosine |
[2] D00045 D00045, D01370 D01370 💬 |
ADORA1 [5] ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism [17] Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 [1] 13 💬 |
8 |
2-cda, 2-chloro-2’-deoxy-ß-d-adenosine |
Adenosine |
[2] D00045 D00045, D01370 D01370 💬 |
ADORA1 [5] ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism [17] Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 [1] 13 💬 |
9 |
2-chloro-2'-deoxy-beta-d-adenosine (2-cda) |
Adenosine |
[2] D00045 D00045, D01370 D01370 💬 |
ADORA1 [5] ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism [17] Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 [1] 13 💬 |
10 |
2-chloro-2'-deoxy-ß-d-adenosine (2-cda) |
Adenosine |
[2] D00045 D00045, D01370 D01370 💬 |
ADORA1 [5] ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism [17] Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 [1] 13 💬 |
11 |
2-chloro-2'-deoxyadenosine (2-cda) |
Cladribine |
[1] D01370 D01370 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
013 [1] 13 💬 |
12 |
2-chloro-2’-deoxy-beta-d-adenosine (2-cda) |
Adenosine |
[2] D00045 D00045, D01370 D01370 💬 |
ADORA1 [5] ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism [17] Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 [1] 13 💬 |
13 |
2-chloro-2’-deoxy-ß-d-adenosine (2-cda) |
Adenosine |
[2] D00045 D00045, D01370 D01370 💬 |
ADORA1 [5] ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism [17] Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 [1] 13 💬 |
14 |
2-chloro-2’-deoxyadenosine (2-cda) |
Cladribine |
[1] D01370 D01370 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
013 [1] 13 💬 |
15 |
Adeno-associated virus serotype 2/6 encoding human alpha-galactosidase a cdna |
Agalsidase alfa |
[1] D02784 D02784 💬 |
GLA [1] GLA 💬 |
Galactose metabolism [6] Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 [1] 19 💬 |
16 |
Allo-asc-cd |
- |
- |
- |
- |
096 [1] 96 💬 |
17 |
Anti cd3 monoclonal antibody |
- |
- |
- |
- |
097 [1] 97 💬 |
18 |
Anti-cd19-car-t cells |
- |
- |
- |
- |
049 [1] 49 💬 |
19 |
Anti-cd20 b cell depletion with truxima |
- |
- |
- |
- |
049 [1] 49 💬 |
20 |
Anti-cd20 small modular immunopharmaceutical, wye-400087 |
- |
- |
- |
- |
046 [1] 46 💬 |
21 |
Anti-cd25 humanized monoclonal antibody |
- |
- |
- |
- |
013 [1] 13 💬 |
22 |
Anti-cd28dab |
- |
- |
- |
- |
049 [3] 49, 53, 160 💬 |
23 |
Anti-cd3 |
Muromonab |
[1] D05092 D05092 💬 |
CD3D [3] CD3D, CD3E, CD3G 💬 |
Chagas disease [11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
096 [2] 96, 97 💬 |
24 |
Anti-cd3 monoclonal antibody |
Muromonab |
[1] D05092 D05092 💬 |
CD3D [3] CD3D, CD3E, CD3G 💬 |
Chagas disease [11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
096 [2] 96, 97 💬 |
25 |
Anti-cd40l |
Toralizumab |
[1] D06193 D06193 💬 |
CD40LG [1] CD40LG 💬 |
Allograft rejection [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, Malaria, NF-kappa B signaling pathway, Primary immunodeficiency, Systemic lupus erythematosus, T cell receptor signaling pathway, Toxoplasmosis, Viral myocarditis |
063 [1] 63 💬 |
26 |
Anti-cd40ldab |
- |
- |
- |
- |
063 [1] 63 💬 |
27 |
Anti-cd45 |
- |
- |
- |
- |
060 [3] 60, 65, 285 💬 |
28 |
Anti-cd52 monoclonal antibody |
- |
- |
- |
- |
013 [1] 13 💬 |
29 |
Ap-cd/ld |
- |
- |
- |
- |
006 [1] 6 💬 |
30 |
Autologous cd34+ cell transduced with g2scid vector |
- |
- |
- |
- |
065 [1] 65 💬 |
31 |
Autologous cd34+ cells transduced ex-vivo with the pcclchimgp91/vsvg lentiviral vector |
- |
- |
- |
- |
065 [1] 65 💬 |
32 |
Autologous cd34+ cells transduced with a lentiviral vector containing the human sgsh gene |
- |
- |
- |
- |
019 [1] 19 💬 |
33 |
Autologous cd34+ cells transduced with a lentiviral vector encoding the arsa cdna |
- |
- |
- |
- |
019 [1] 19 💬 |
34 |
Autologous cd34+ cells transduced with lenti-d vector encoding abcd1 cdna |
- |
- |
- |
- |
020 [1] 20 💬 |
35 |
Autologous cd34+ cells transduced with the lentiviral vector containing the human wiskott aldrich sy |
- |
- |
- |
- |
065 [1] 65 💬 |
36 |
Autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with lentiviral vector that encodes for the human wiskott aldrich syndrome (was) cdna sequence |
- |
- |
- |
- |
065 [1] 65 💬 |
37 |
Autologous cd34+ hscs transduced ex vivo with efs lentiviral vector encoding for the human ada gene |
- |
- |
- |
- |
065 [1] 65 💬 |
38 |
Autologous cd34+cells transduced with the w1.6_hwasp_wpre (vsvg) lentiviral vector |
- |
- |
- |
- |
065 [1] 65 💬 |
39 |
Autologous cd34-selected peripheral blood stem cells transplant |
- |
- |
- |
- |
096 [1] 96 💬 |
40 |
Autologous cd4+t cells stimulated and expanded ex vivo by a mog peptide modified by the introduction of a thioreductase motif into the flanking residues of the t cell epitope |
- |
- |
- |
- |
013 [1] 13 💬 |
41 |
Autologous haematopoietic stem cells transduced with lentiviral vector lenti-d encoding the human abcd1 cdna |
- |
- |
- |
- |
020 [1] 20 💬 |
42 |
Autologous stemcell transplantation with cd (cluster of differentiation) 34 selected stem cells |
- |
- |
- |
- |
051 [1] 51 💬 |
43 |
Bardoxolone methyl, cddo-me, cddo-methyl ester, nsc 713200, chemical name: oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester |
Bardoxolone |
[2] D09584 D09584, D09585 D09585 💬 |
- |
- |
086 [1] 86 💬 |
44 |
Biologic: ic14 (monoclonal antibody against human cd14) |
- |
- |
- |
- |
002 [1] 2 💬 |
45 |
Blinded cdca 250 mg tid |
Chenodeoxycholic acid |
[1] D00163 D00163 💬 |
NR1H4 [1] NR1H4 💬 |
Bile secretion [1] Bile secretion |
263 [1] 263 💬 |
46 |
Bt061 (cd4 monoclonal antibody) |
- |
- |
- |
- |
046 [1] 46 💬 |
47 |
Cd |
- |
- |
- |
- |
006 [6] 6 , 46, 51, 96, 97, 265 💬 |
48 |
Cd-4 guided therapy interruption |
- |
- |
- |
- |
265 [1] 265 💬 |
49 |
Cd-ld cr |
- |
- |
- |
- |
006 [1] 6 💬 |
50 |
Cd-ld ir |
- |
- |
- |
- |
006 [1] 6 💬 |
51 |
Cd19-directed humanised afucosylated monoclonal antibody |
- |
- |
- |
- |
011 [1] 11 💬 |
52 |
Cd3/cd19 depleted leukocytes |
- |
- |
- |
- |
284 [1] 284 💬 |
53 |
Cd3/cd19 neg allogeneic bmt |
- |
- |
- |
- |
065 [1] 65 💬 |
54 |
Cd3/cd19 negative allogeneic hematopoietic stem cells |
- |
- |
- |
- |
065 [1] 65 💬 |
55 |
Cd3/cd19 negative hematopoietic stem cells |
- |
- |
- |
- |
085 [1] 85 💬 |
56 |
Cd34 selected autologous hematopoietic cells |
- |
- |
- |
- |
051 [1] 51 💬 |
57 |
Cd34 stem cell selection therapy |
- |
- |
- |
- |
060 [3] 60, 65, 284 💬 |
58 |
Cd34+ |
- |
- |
- |
- |
065 [1] 65 💬 |
59 |
Cd34+ bone marrow stem cells intravitreal |
- |
- |
- |
- |
090 [1] 90 💬 |
60 |
Cd34+ cells |
- |
- |
- |
- |
285 [1] 285 💬 |
61 |
Cd34+ cells transduced with ada retrovir |
- |
- |
- |
- |
065 [1] 65 💬 |
62 |
Cd34+ enriched, t cell depleted donor stem cell product |
- |
- |
- |
- |
326 [1] 326 💬 |
63 |
Cd34+ hscs transduced with the lentivirus vector, vsv-g pseudotyped cl20-4i-ef1a-h?c-opt |
- |
- |
- |
- |
065 [1] 65 💬 |
64 |
Cd34+ selected cells |
- |
- |
- |
- |
285 [1] 285 💬 |
65 |
Cd34+cells |
- |
- |
- |
- |
065 [2] 65, 285 💬 |
66 |
Cd34+sc |
- |
- |
- |
- |
051 [1] 51 💬 |
67 |
Cd45ra depleted leukocytes |
- |
- |
- |
- |
284 [1] 284 💬 |
68 |
Cd45ra-depleted dli |
- |
- |
- |
- |
060 [2] 60, 65 💬 |
69 |
Cd62l- tem |
- |
- |
- |
- |
060 [1] 60 💬 |
70 |
Cdca |
Chenodeoxycholic acid |
[1] D00163 D00163 💬 |
NR1H4 [1] NR1H4 💬 |
Bile secretion [1] Bile secretion |
263 [1] 263 💬 |
71 |
Cdca weight-based dose tid |
Chenodeoxycholic acid |
[1] D00163 D00163 💬 |
NR1H4 [1] NR1H4 💬 |
Bile secretion [1] Bile secretion |
263 [1] 263 💬 |
72 |
Cdmard |
- |
- |
- |
- |
046 [1] 46 💬 |
73 |
Cdnf |
- |
- |
- |
- |
006 [1] 6 💬 |
74 |
Cdp |
- |
- |
- |
- |
046 [1] 46 💬 |
75 |
Cdp 6038 sc |
- |
- |
- |
- |
046 [1] 46 💬 |
76 |
Cdp3194 |
- |
- |
- |
- |
049 [1] 49 💬 |
77 |
Cdp323 |
CDP323 |
- |
- |
- |
013 [1] 13 💬 |
78 |
Cdp6038 |
- |
- |
- |
- |
046 [2] 46, 96 💬 |
79 |
Cdp7657 |
- |
- |
- |
- |
049 [1] 49 💬 |
80 |
Cdp870 |
- |
- |
- |
- |
046 [3] 46, 96, 271 💬 |
81 |
Cdp870 100mg |
- |
- |
- |
- |
046 [1] 46 💬 |
82 |
Cdp870 200mg |
- |
- |
- |
- |
046 [1] 46 💬 |
83 |
Cdp870 400mg |
- |
- |
- |
- |
046 [1] 46 💬 |
84 |
Cdp870 fab'-peg |
- |
- |
- |
- |
046 [1] 46 💬 |
85 |
Cdx |
- |
- |
- |
- |
222 [3] 222, 223, 240 💬 |
86 |
Cdx 6114 |
- |
- |
- |
- |
240 [1] 240 💬 |
87 |
Cdx-1135 |
- |
- |
- |
- |
222 [2] 222, 223 💬 |
88 |
Cdz173 |
- |
- |
- |
- |
053 [2] 53, 65 💬 |
89 |
Cellule cd34+ autologhe trasdotte con idua lv codificante per il cdna dell'alfa-l-iduronidasi |
- |
- |
- |
- |
019 [1] 19 💬 |
90 |
Certolizumab pegol (cdp870) |
Certolizumab pegol |
[1] D03441 D03441 💬 |
TNF [1] TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 [2] 46, 96 💬 |
91 |
Certolizumab pegol (cdp870, czp) |
Certolizumab pegol |
[1] D03441 D03441 💬 |
TNF [1] TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
096 [1] 96 💬 |
92 |
Certolizumab pegol (cdp870, tradename cimzia) |
Certolizumab pegol |
[1] D03441 D03441 💬 |
TNF [1] TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 [1] 46 💬 |
93 |
Certolizumab pegol (cdp870, tradename cimzia)(prefilled syringes at the dose of 200mg) |
Certolizumab pegol |
[1] D03441 D03441 💬 |
TNF [1] TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 [1] 46 💬 |
94 |
Chimeric human/mouse anti-cd-20 monoclonal antibody |
- |
- |
- |
- |
046 [1] 46 💬 |
95 |
Chx a-dtpa anti-cd66 antibody |
Pentetic acid |
[1] D05422 D05422 💬 |
- |
- |
028 [1] 28 💬 |
96 |
Chx-a-dtpa-anti-cd66 |
Pentetic acid |
[1] D05422 D05422 💬 |
- |
- |
028 [1] 28 💬 |
97 |
Combination of a single dose anti-cd20 antibody and bortezomib |
Bortezomib |
[1] D03150 D03150 💬 |
PSMB5 [1] PSMB5 💬 |
Alzheimer disease [8] Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia |
061 [1] 61 💬 |
98 |
Cryopreserved autologous cd34+ cells transduced with a lentiviral vector containing human sgsh gene |
- |
- |
- |
- |
019 [1] 19 💬 |
99 |
Cryopreserved efs-ada lv transduced patient cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
100 |
Cryopreserved g2scid lentiviral vector transduced patient cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
101 |
Cytolytic cd4+ t cells |
- |
- |
- |
- |
013 [1] 13 💬 |
102 |
Cytoreductive regimen followed by a cd34+e- selected allogeneic stem cell transplant |
- |
- |
- |
- |
062 [1] 62 💬 |
103 |
D-methylphenidate |
Methylphenidate |
[2] D01296 D01296, D04999 D04999 💬 |
SLC6A2 [2] SLC6A2, SLC6A3 💬 |
Alcoholism [7] Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
084 [1] 84 💬 |
104 |
Daclizumab (anti-cd25 humanized monoclonal antibody) |
Daclizumab |
[1] D03639 D03639 💬 |
IL2RA [1] IL2RA 💬 |
Cytokine-cytokine receptor interaction [11] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
013 [1] 13 💬 |
105 |
Depletion in cd45ra graft donor |
- |
- |
- |
- |
065 [1] 65 💬 |
106 |
Device: cell processing for tcrabeta+/cd19+ depletion |
- |
- |
- |
- |
065 [1] 65 💬 |
107 |
Device: cell processing for tcraß+/cd19+ depletion |
- |
- |
- |
- |
065 [1] 65 💬 |
108 |
Device: clinimacs® cd34 reagent system cell sorter device |
- |
- |
- |
- |
065 [1] 65 💬 |
109 |
Device: miltenyi cd34 reagent system |
- |
- |
- |
- |
060 [1] 60 💬 |
110 |
Diltiazem |
Diltiazem |
[3] D00616 D00616, D03830 D03830, D07845 D07845 💬 |
CACNA1C [4] CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes [36] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 [3] 51, 58, 86 💬 |
111 |
Diltiazem gel 2% |
Diltiazem |
[3] D00616 D00616, D03830 D03830, D07845 D07845 💬 |
CACNA1C [4] CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes [36] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 [1] 51 💬 |
112 |
Diltiazem hydrochloride |
Diltiazem |
[3] D00616 D00616, D03830 D03830, D07845 D07845 💬 |
CACNA1C [4] CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes [36] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 [1] 86 💬 |
113 |
Duodopa ld/cd 20/5 mg/ml |
- |
- |
- |
- |
006 [1] 6 💬 |
114 |
Ef1as-ada lentiviral vector gene modified autologous cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
115 |
Ef1as-ada lentiviral vector transduced patient cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
116 |
Engineered humanized monoclonal anti-human cd19 antibody. |
- |
- |
- |
- |
046 [1] 46 💬 |
117 |
Engineered humanized monoclonal anti-human cd19 antibody. lot numbers: 1-fin-1588 (9.6mg/ml) |
- |
- |
- |
- |
046 [1] 46 💬 |
118 |
Er cd-ld |
- |
- |
- |
- |
006 [1] 6 💬 |
119 |
Ex vivo culture and transduction of the patient's autologous cd34+ hsc with lentivirus vector vsv-g pseudotyped cl20- 4i-ef1a-hyc-opt vector |
- |
- |
- |
- |
065 [1] 65 💬 |
120 |
Ex-vivo expanded autologous human keratinocytes suspension containing epidermal stem cells genetically modified with a gamma-retroviral (rv) vector expressing the full-length lamb3 cdna. |
- |
- |
- |
- |
036 [1] 36 💬 |
121 |
Fc- and cdr-modified humanised monoclonal antibody against c5 |
- |
- |
- |
- |
011 [3] 11, 62, 109 💬 |
122 |
G1xcgd transduced cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
123 |
Gene-transduced autologous cd34+ stem cells |
- |
- |
- |
- |
065 [1] 65 💬 |
124 |
Genetic: infusion of autologous cryopreserved efs-ada lv cd34+ cells (otl-101) |
- |
- |
- |
- |
065 [1] 65 💬 |
125 |
Genetic: infusion of autologous efs-ada lv cd34+ (otl-101) |
- |
- |
- |
- |
065 [1] 65 💬 |
126 |
Genetic: infusion of autologous efs-ada lv cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
127 |
Gsk2018682 cd2 capsule |
- |
- |
- |
- |
013 [1] 13 💬 |
128 |
Gsk2018682 cd3 micronised tablet |
- |
- |
- |
- |
013 [1] 13 💬 |
129 |
Gsk2018682 cd3 non-micronised tablet |
- |
- |
- |
- |
013 [1] 13 💬 |
130 |
Gsk2018682 cd3 non-micronised tablet in fed state |
- |
- |
- |
- |
013 [1] 13 💬 |
131 |
Human monoclonal antibody directed against cd20 on b-cells |
- |
- |
- |
- |
046 [1] 46 💬 |
132 |
Humanised anti-cd 20 antibody |
- |
- |
- |
- |
046 [1] 46 💬 |
133 |
Humanised anti-cd4 igg1 monoclonal |
- |
- |
- |
- |
046 [1] 46 💬 |
134 |
Humanized recombinant igg4 monoclonal antibody against cd-127 |
- |
- |
- |
- |
097 [1] 97 💬 |
135 |
Humax-cd20 |
Ofatumumab |
[1] D09314 D09314 💬 |
MS4A1 [1] MS4A1 💬 |
Hematopoietic cell lineage [1] Hematopoietic cell lineage |
013 [2] 13, 46 💬 |
136 |
Humax-cd38 |
- |
- |
- |
- |
028 [2] 28, 63 💬 |
137 |
Humax-cd4 |
- |
- |
- |
- |
046 [1] 46 💬 |
138 |
Indium 111-radiolabelled anti-cd66 |
Indium |
- |
- |
- |
028 [1] 28 💬 |
139 |
Indium 111 labelled anti-cd66 |
Indium |
- |
- |
- |
028 [1] 28 💬 |
140 |
Inebilizumab |
Inebilizumab |
[1] D11757 D11757 💬 |
CD19 [1] CD19 💬 |
B cell receptor signaling pathway [5] B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency |
011 [3] 11, 13, 300 💬 |
141 |
Ipx203 er cd-ld |
- |
- |
- |
- |
006 [1] 6 💬 |
142 |
Ir cd-ld |
- |
- |
- |
- |
006 [1] 6 💬 |
143 |
Ir cd-ld (carbidopa-levodopa) tablets |
Carbidopa |
[2] D00059 D00059, D00558 D00558 💬 |
DDC [6] DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism [16] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 [1] 6 💬 |
144 |
Ir ld / cd |
- |
- |
- |
- |
006 [1] 6 💬 |
145 |
Ir ld/cd |
- |
- |
- |
- |
006 [1] 6 💬 |
146 |
Ld/cd |
- |
- |
- |
- |
006 [1] 6 💬 |
147 |
Lentiviral vector transduced cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
148 |
Levodopa/carbidopa (ld/cd) |
Carbidopa |
[2] D00059 D00059, D00558 D00558 💬 |
DDC [6] DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism [16] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 [1] 6 💬 |
149 |
Methylphenidate |
Methylphenidate |
[2] D01296 D01296, D04999 D04999 💬 |
SLC6A2 [2] SLC6A2, SLC6A3 💬 |
Alcoholism [7] Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 [7] 6 , 13, 34, 84, 113, 179, 206 💬 |
150 |
Methylphenidate (mpd) |
Methylphenidate |
[2] D01296 D01296, D04999 D04999 💬 |
SLC6A2 [2] SLC6A2, SLC6A3 💬 |
Alcoholism [7] Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 [1] 6 💬 |
151 |
Methylphenidate (overencapsulated) |
Methylphenidate |
[2] D01296 D01296, D04999 D04999 💬 |
SLC6A2 [2] SLC6A2, SLC6A3 💬 |
Alcoholism [7] Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
084 [1] 84 💬 |
152 |
Methylphenidate 10mg tablets |
Methylphenidate |
[2] D01296 D01296, D04999 D04999 💬 |
SLC6A2 [2] SLC6A2, SLC6A3 💬 |
Alcoholism [7] Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
084 [1] 84 💬 |
153 |
Methylphenidate hydrochloride |
Methylphenidate |
[2] D01296 D01296, D04999 D04999 💬 |
SLC6A2 [2] SLC6A2, SLC6A3 💬 |
Alcoholism [7] Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 [2] 6 , 13 💬 |
154 |
Methylphenidate modified release |
Methylphenidate |
[2] D01296 D01296, D04999 D04999 💬 |
SLC6A2 [2] SLC6A2, SLC6A3 💬 |
Alcoholism [7] Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 [1] 13 💬 |
155 |
Methylphenidate modified release 20 mg |
Methylphenidate |
[2] D01296 D01296, D04999 D04999 💬 |
SLC6A2 [2] SLC6A2, SLC6A3 💬 |
Alcoholism [7] Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 [1] 13 💬 |
156 |
Methylphenidate modified release 30 mg |
Methylphenidate |
[2] D01296 D01296, D04999 D04999 💬 |
SLC6A2 [2] SLC6A2, SLC6A3 💬 |
Alcoholism [7] Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 [1] 13 💬 |
157 |
Methylphenidate modified release 40 mg |
Methylphenidate |
[2] D01296 D01296, D04999 D04999 💬 |
SLC6A2 [2] SLC6A2, SLC6A3 💬 |
Alcoholism [7] Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 [1] 13 💬 |
158 |
Methylphenidate, fluoxetin, risperidone |
Fluoxetine |
[5] D00326 D00326, D00426 D00426, D00823 D00823, D01296 D01296, D04999 D04999 💬 |
DRD2 [5] DRD2, HTR2A, SLC6A2, SLC6A3, SLC6A4 💬 |
Alcoholism [14] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Rap1 signaling pathway, Serotonergic synapse, Synaptic vesicle cycle, cAMP signaling pathway |
179 [2] 179, 206 💬 |
159 |
Muromonab |
Muromonab |
[1] D05092 D05092 💬 |
CD3D [3] CD3D, CD3E, CD3G 💬 |
Chagas disease [11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
060 [1] 60 💬 |
160 |
Muromonab-cd3 |
Muromonab |
[1] D05092 D05092 💬 |
CD3D [3] CD3D, CD3E, CD3G 💬 |
Chagas disease [11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
060 [1] 60 💬 |
161 |
Ni-0401 (anti-cd3 mab) |
Muromonab |
[1] D05092 D05092 💬 |
CD3D [3] CD3D, CD3E, CD3G 💬 |
Chagas disease [11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
096 [1] 96 💬 |
162 |
Ono-2160/cd |
- |
- |
- |
- |
006 [1] 6 💬 |
163 |
Open-label cdca 250 mg tid |
Chenodeoxycholic acid |
[1] D00163 D00163 💬 |
NR1H4 [1] NR1H4 💬 |
Bile secretion [1] Bile secretion |
263 [1] 263 💬 |
164 |
Other: cd lfd |
- |
- |
- |
- |
096 [1] 96 💬 |
165 |
Other: cd-treat diet |
- |
- |
- |
- |
096 [1] 96 💬 |
166 |
Other: crohn's disease treatment-with-eating diet (cd-treat diet) |
- |
- |
- |
- |
096 [1] 96 💬 |
167 |
Other: diet-cd |
- |
- |
- |
- |
096 [1] 96 💬 |
168 |
Phagocyte oxidase subunit transduced cd34 hematopoietic stem cells |
- |
- |
- |
- |
065 [1] 65 💬 |
169 |
Plerixafor mobilization of autologous cd117 stem cells |
Plerixafor |
[1] D08971 D08971 💬 |
CXCR4 [1] CXCR4 💬 |
Axon guidance [12] Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor |
299 [1] 299 💬 |
170 |
Procedure: autologous cd34+hpc transplantation (hsct) |
- |
- |
- |
- |
049 [1] 49 💬 |
171 |
Procedure: cd3-depleted hematopoietic cell transplantation |
- |
- |
- |
- |
060 [1] 60 💬 |
172 |
Procedure: cd34 selected haploidentical pbsct |
- |
- |
- |
- |
285 [1] 285 💬 |
173 |
Procedure: cd34+ peripheral blood stem cell reinfusion |
- |
- |
- |
- |
049 [1] 49 💬 |
174 |
Procedure: cd3±cd19 depleted hematopoietic stem cell transplantation |
- |
- |
- |
- |
060 [1] 60 💬 |
175 |
Procedure: repair of cdh w/alloderm |
- |
- |
- |
- |
294 [1] 294 💬 |
176 |
Procedure: repair of cdh w/sis gold |
Gold |
- |
- |
- |
294 [1] 294 💬 |
177 |
Rag1 lv cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
178 |
Recombinant adeno-associated virus 2/6 vector encoding the cdna for human alpha galactosidase a |
- |
- |
- |
- |
019 [1] 19 💬 |
179 |
Rescue medication cdca 250 mg tid |
Chenodeoxycholic acid |
[1] D00163 D00163 💬 |
NR1H4 [1] NR1H4 💬 |
Bile secretion [1] Bile secretion |
263 [1] 263 💬 |
180 |
Retroviral sf71-gp91phox transduced cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
181 |
Rituximab (anti-cd20) |
Rituximab |
[1] D02994 D02994 💬 |
MS4A1 [1] MS4A1 💬 |
Hematopoietic cell lineage [1] Hematopoietic cell lineage |
053 [1] 53 💬 |
182 |
Routine treatment of cd |
- |
- |
- |
- |
096 [1] 96 💬 |
183 |
Semi continuous intra-oral administration of ld/cd |
- |
- |
- |
- |
006 [1] 6 💬 |
184 |
Standard ld/cd |
- |
- |
- |
- |
006 [1] 6 💬 |
185 |
Suspension of autologous cd34+cells transduced with the g1xcgd viral vector |
- |
- |
- |
- |
065 [1] 65 💬 |
186 |
T-cell depleted & cd34+select/w/stemcell enriched product |
- |
- |
- |
- |
065 [1] 65 💬 |
187 |
Tl011, anti cd20, for the treatment of rheumatoid arthritis |
- |
- |
- |
- |
046 [1] 46 💬 |
188 |
Transduced cd34+ cells |
- |
- |
- |
- |
285 [1] 285 💬 |
189 |
Transduced patient cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
190 |
Yttrium-90 radiolabelled anti-cd66 antibody |
Yttrium Y-90 |
- |
- |
- |
028 [1] 28 💬 |
191 |
Yttrium90 radiolabelled anticd66 |
- |
- |
- |
- |
028 [1] 28 💬 |